STOCK TITAN

Zai Lab (ZLAB) Stock News

ZLAB NASDAQ

Zai Lab Limited reports developments for a commercial-stage biopharmaceutical company with American depositary shares traded under ZLAB and ordinary shares listed in Hong Kong. The company discovers, develops, licenses and commercializes therapies for oncology, immunology, neuroscience and infectious disease, with operations based in China and the United States.

Recurring company updates include financial results, regulatory designations, clinical and preclinical data, collaborations and product updates across programs such as zocilurtatug pelitecan, ZL-1503, ZL-6201 and ZL-1222. Updates also address regional commercial products and pipeline assets including ZEJULA, VYVGART, KarXT and TIVDAK.

Rhea-AI Summary

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) secured inclusion of five commercial medicines in China’s 2026 National Reimbursement Drug List, effective January 1, 2027.

KarXT and VYVGART Hytrulo received first-time listings for adult schizophrenia and adult anti-acetylcholine receptor antibody-positive generalized myasthenia gravis, respectively. The latter is an autoimmune condition causing muscle weakness. Reimbursement listings were renewed for NUZYRA for specified bacterial infections, QINLOCK for previously treated advanced gastrointestinal stromal tumors, and AUGTYRO for specified lung cancers and gene fusion-positive solid tumors. Zai Lab expects the new listings to broaden patient access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
none
-
Rhea-AI Summary

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) announced senior management participation in two investor conferences in London in November 2026.

UBS Global Biopharma Conference meetings are on November 17. The Jefferies Global Healthcare Conference runs November 18–19, with a fireside chat on November 18 at 10:30AM GMT. UBS participation is limited to one-on-one meetings; Jefferies includes a presentation and one-on-one meetings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
none
-
Rhea-AI Summary

Zai Lab (ZLAB) reported preliminary first-in-human results for ZL-1503 showing sustained inhibition of an atopic dermatitis biomarker in healthy volunteers.

The Phase 1/1b single-dose findings included 48 healthy volunteers. Doses of 200–1,000 mg achieved at least 90% inhibition of pSTAT6, a signaling biomarker, through Week 12. Other inflammatory biomarkers also declined. The antibody had an approximately 40–50-day half-life, the time for its serum concentration to fall by half. No serious adverse events, dose-limiting toxicities or anti-drug antibodies were detected. Zai Lab targets maintenance dosing once every 12 weeks, subject to further evaluation.

The company expects repeated-dose data in patients with moderate-to-severe atopic dermatitis in the first half of 2027. Enrollment is complete in a study bridging intravenous and under-the-skin administration, with initial data expected in 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.53%
Tags
none
Rhea-AI Summary

Zai Lab (ZLAB) reported a 40.0% confirmed tumor response rate for zoci in previously treated advanced extrapulmonary neuroendocrine carcinomas.

The Phase 1b/2 trial's investigator-assessed efficacy population included 60 patients. Median response duration was 5.6 months; response rates were 35.9% in gastroenteropancreatic cancers and 47.6% in other subtypes. Among 133 patients assessed for safety, 12.8% had treatment-related adverse events of Grade 3 or higher. Two patients had Grade 2 lung inflammation, and 0.8% discontinued because of treatment-related events; no treatment-related deaths occurred.

Enrollment in the Phase 2 second-line expansion cohort is complete, but recently enrolled patients' data remain immature. Zai Lab plans to pursue a potential accelerated approval pathway using the single-arm study, with topline data expected in 2027. It also plans a global Phase 3 first-line maintenance trial in 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
-
Rhea-AI Summary

Zai Lab (ZLAB) reported third-quarter 2026 revenue of $108.2 million while advancing zoci toward additional late-stage cancer trials and potential submissions. Revenue fell from $116.1 million a year earlier, although net product revenue rose 2% sequentially. Net loss widened to $46.1 million from $36.0 million, primarily reflecting inventory write-downs. Cash, restricted cash and short-term investments totaled $659.7 million at September 30; an October private placement subsequently raised approximately $241.2 million net.

Zoci plus atezolizumab produced an 81.8% confirmed response rate in 33 evaluable first-line small cell lung cancer patients. Zai Lab plans a global Phase 3 combination study by year-end 2026 and sees potential U.S. accelerated approval submissions in 2027. Other updates included a positive VYVGART myositis trial and discontinuation of its Sjögren’s disease trial for futility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
-
Rhea-AI Summary

Zai Lab (ZLAB) reported an 81.8% confirmed response rate for zoci plus atezolizumab in first-line extensive-stage small cell lung cancer. The global Phase 1b trial's September 2026 cutoff included 33 patients receiving the recommended Phase 3 zoci dose of 1.6 mg/kg. Estimated six-month progression-free survival, measuring survival without cancer worsening, was 81.9%. Among 15 patients with at least six months of follow-up, median progression-free survival and response duration were not reached after median follow-up of 10 months.

Severe or worse treatment-emergent adverse events occurred in 21.2% of patients on this doublet, versus 76.9% among 13 patients receiving zoci, atezolizumab and carboplatin across dose levels. The triplet's response rate was 92.3%. Zai Lab expects to initiate a global randomized Phase 3 trial of zoci with an immuno-oncology regimen by year-end 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.03%
Tags
none
Rhea-AI Summary

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) signed a securities purchase agreement for a private placement expected to raise approximately $250 million. The financing involves 11,340,000 American Depositary Shares (ADSs) at $22.04 each, with each ADS representing ten ordinary shares. Expected gross proceeds exclude placement agent fees and other offering expenses.

TCGX leads the financing, which includes new and existing investors. Zai Lab expects closing on or about October 27, 2026, subject to customary closing conditions. The company intends to use net proceeds primarily to support continued global development of zocilurtatug pelitecan (zoci), its DLL3-targeting antibody-drug conjugate, a targeted drug-delivery treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.03%
Tags
private placement
-
Rhea-AI Summary

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) will report third-quarter 2026 financial results and recent corporate updates on November 5, 2026. Results will be released before U.S. equity markets open, followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT). A replay will be available on the company’s website shortly after the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.51%
Tags
earnings date
-
Rhea-AI Summary

Zai Lab (ZLAB) will present its first clinical trial data for ZL-1503 at the ACAAI meeting on November 13, 2026. The presentation covers healthy volunteers in the Phase 1/1b trial of the internally developed antibody, which targets IL-13 and IL-31 receptor signaling in atopic diseases.

The findings will include single-dose pharmacokinetic data, describing how the drug moves through the body, and pharmacodynamic data, describing its effects on disease-related biomarkers across different doses. Initial safety data and immune responses to the antibody will also be presented. The poster is scheduled for 2:50 p.m. Mountain Time in Phoenix. Zai Lab will hold an investor call and webcast that day at 8:00 a.m. ET to discuss the presented data and clinical trial plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.60%
Tags
Rhea-AI Summary

Zai Lab (ZLAB) will present first global zoci trial data for first-line extensive-stage small cell lung cancer at ESMO on October 26, 2026. The Phase 1b/1c trial cohort is evaluating zoci with atezolizumab, with or without carboplatin. Zai Lab has scheduled an investor call to discuss the data and its zoci clinical trial plans on October 23.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags

FAQ

What is the current stock price of Zai Lab (ZLAB)?

Zai Lab (ZLAB) last closed at $23.53.

What is the market cap of Zai Lab (ZLAB)?

The market cap of Zai Lab (ZLAB) is approximately $2.9B.